• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

经口腔黏膜给药的α干扰素在动物疾病预防和治疗中的应用。

Use of oromucosally administered interferon-alpha in the prevention and treatment of animal diseases.

作者信息

Dec M, Puchalski A

机构信息

University of Life Sciences, Faculty of Veterinary Medicine, Institute of Biological Bases of Animal Diseases, Department of Veterinary Prevention, Lublin, Poland.

出版信息

Pol J Vet Sci. 2008;11(2):175-86.

PMID:18683548
Abstract

Interferon-alpha (IFN-alpha) is well known as a clinically effective antiviral and antineoplastic therapeutic agent. It has also been shown to have immunoregulatory properties. IFN-alpha stimulates a cell-mediated innate immune response and then participates in the transition of the initial host innate response to an effective adaptive immune response. IFN-alpha is produced in small quantities in nasal secretions during viral infections, prompting many authors to suggest that low-dose oromucosal administration of IFN-alpha effectively mimics nature. Moreover, the injectable high-dose interferon therapy currently approved for various human disorders causes numerous side effects. By contrast, oromucosal administration of IFN-alpha is not associated with toxic effects. Another distinct advantage is ease of administration: the IFN can be dissolved in drinking water or administered by nebulization to the oral or nasal cavity. This review describes the current state of knowledge concerning orally administered IFN-alpha, of both human and animal origin, as a prophylactic or therapeutic agent in veterinary medicine. We present the effects of IFN-alpha in such animals as cattle, pigs, horses, cats, dogs and chickens, and attempt to explain its mechanism of action following oromucosal administration. It is hoped that this review of the medical literature on the use of IFN-alpha in animals will give practitioners a better understanding of the challenges and benefits of using this interesting cytokine in clinical practice.

摘要

α干扰素(IFN-α)作为一种临床有效的抗病毒和抗肿瘤治疗药物广为人知。它也已被证明具有免疫调节特性。IFN-α刺激细胞介导的先天性免疫反应,然后参与宿主初始先天性反应向有效的适应性免疫反应的转变。在病毒感染期间,鼻分泌物中会少量产生IFN-α,这促使许多作者提出,低剂量经口黏膜给予IFN-α可有效模拟自然情况。此外,目前批准用于各种人类疾病的注射用高剂量干扰素疗法会引起许多副作用。相比之下,经口黏膜给予IFN-α不会产生毒性作用。另一个明显的优点是给药方便:IFN可以溶解在饮用水中或通过雾化吸入给药至口腔或鼻腔。这篇综述描述了关于人源和动物源口服IFN-α作为兽医学预防或治疗药物的现有知识状况。我们介绍了IFN-α在牛、猪、马、猫、狗和鸡等动物中的作用,并试图解释其经口黏膜给药后的作用机制。希望这篇关于动物使用IFN-α的医学文献综述能让从业者更好地理解在临床实践中使用这种有趣的细胞因子所面临的挑战和益处。

相似文献

1
Use of oromucosally administered interferon-alpha in the prevention and treatment of animal diseases.经口腔黏膜给药的α干扰素在动物疾病预防和治疗中的应用。
Pol J Vet Sci. 2008;11(2):175-86.
2
Interferon-alpha as an immunotherapeutic protein.α干扰素作为一种免疫治疗蛋白。
J Leukoc Biol. 2002 Apr;71(4):565-81.
3
Oromucosal cytokine therapy: mechanism(s) of action.
Taehan Kan Hakhoe Chi. 2002 Jun;8(2):125-31.
4
Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons.重组α干扰素的生物学特性:干扰素发现40周年
Cancer Res. 1998 Jun 15;58(12):2489-99.
5
Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.α干扰素与低剂量白细胞介素-2联合免疫疗法治疗日本转移性肾细胞癌患者的临床疗效
Urol Oncol. 2009 Nov-Dec;27(6):598-603. doi: 10.1016/j.urolonc.2008.07.023. Epub 2008 Sep 25.
6
A perspective on the clinical effectiveness and tolerance of interferon-alpha.
Semin Oncol. 1998 Feb;25(1 Suppl 1):3-8.
7
IFN-alpha and novel strategies of combination therapy for cancer.干扰素-α与癌症联合治疗的新策略
Ann N Y Acad Sci. 2007 Sep;1112:256-68. doi: 10.1196/annals.1415.030. Epub 2007 Jun 13.
8
Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use.α干扰素与癌症:作用机制及临床应用新视角
Biochimie. 2007 Jun-Jul;89(6-7):884-93. doi: 10.1016/j.biochi.2007.04.006. Epub 2007 Apr 21.
9
Oromucosal interferon therapy: marked antiviral and antitumor activity.
J Interferon Cytokine Res. 1999 Feb;19(2):145-55. doi: 10.1089/107999099314298.
10
New developments in interferon therapy.干扰素治疗的新进展。
Eur J Med Res. 2001 Feb 28;6(2):47-65.

引用本文的文献

1
Repurpose but also (nano)-reformulate! The potential role of nanomedicine in the battle against SARS-CoV2.重新定位,也要(纳米)重塑!纳米医学在抗击 SARS-CoV2 中的潜在作用。
J Control Release. 2021 Sep 10;337:258-284. doi: 10.1016/j.jconrel.2021.07.028. Epub 2021 Jul 20.
2
Influence of interferon-based drugs on immunological indices in specific prevention.基于干扰素的药物在特异性预防中对免疫指标的影响。
Vet World. 2020 Feb;13(2):238-244. doi: 10.14202/vetworld.2020.238-244. Epub 2020 Feb 10.
3
Long-term follow-up study after administration of a canine interferon-α preparation for feline gingivitis.
犬用α-干扰素制剂治疗猫牙龈炎后的长期随访研究
J Vet Med Sci. 2020 Feb 26;82(2):232-236. doi: 10.1292/jvms.19-0187. Epub 2019 Dec 31.
4
Innate immune responses induced by the saponin adjuvant Matrix-M in specific pathogen free pigs.无特定病原体猪中皂苷佐剂Matrix-M诱导的天然免疫反应
Vet Res. 2017 May 22;48(1):30. doi: 10.1186/s13567-017-0437-2.
5
Oral administration of interferon-α2b-transformed Bifidobacterium longum protects BALB/c mice against coxsackievirus B3-induced myocarditis.口服干扰素-α2b 转化的长双歧杆菌可预防 BALB/c 小鼠柯萨奇病毒 B3 诱导的心肌炎。
Virol J. 2011 Dec 8;8:525. doi: 10.1186/1743-422X-8-525.
6
Feline herpesvirus-1: ocular manifestations, diagnosis and treatment options.猫疱疹病毒-1:眼部表现、诊断及治疗选择
J Feline Med Surg. 2011 May;13(5):333-46. doi: 10.1016/j.jfms.2011.03.010.
7
Biodegradable nanogels for oral delivery of interferon for norovirus infection.用于诺如病毒感染的干扰素口服递送的可生物降解纳米凝胶。
Antiviral Res. 2011 Feb;89(2):165-73. doi: 10.1016/j.antiviral.2010.11.016. Epub 2010 Dec 7.